
PS FERTILITY

MEDIA KIT

OVERVIEW

PS Fertility is committed to revolutionizing male fertility diagnostics by equipping physicians and patients with advanced tools to uncover the root causes of infertility. By offering innovative solutions like PS Detect, PS Fertility is empowering more couples to get fertility answers. For more information, visit www.psfertility.com.

FAST FACTS

Founded: 2019

Headquarters: Charlottesville, VA

Mission: PS Fertility helps physicians and patients better assess male infertility and provides clear answers to couples.



**EQUIPPING
PHYSICIANS AND
PATIENTS WITH
ADVANCED TOOLS
TO UNCOVER THE ROOT CAUSES OF
INFERTILITY.**

PS FERTILITY

OUR STORY

For decades, fertility diagnostics focused primarily on women, even though up to half of infertility cases involve a male factor. Standard semen analysis offered limited insight, leaving physicians and patients without the answers they deserved.

PS Fertility was founded following breakthrough research by Dr. Jeff Lysiak and Dr. Kodi S. Ravichandran, who discovered that a biomarker called phosphatidylserine, or PS, must be present for egg-sperm fertilization. This scientific advancement became the catalyst for a new kind of company, founded by Kevin Combs, Dr. Lysiak and Dr. Ravichandran. PS Fertility developed a test to check sperm for the presence of PS, thereby determining whether the male is fertile.

Today, PS Fertility addresses a critical gap in reproductive medicine: undiagnosed male infertility. PS Fertility provides physicians and patients with an added insight to help determine the most effective fertility treatment to achieve a successful pregnancy.

↗ THE PROBLEM

STANDARD TESTS FALL SHORT

Traditional semen analysis measures sperm count and motility, but not actual fertilization capability.

PHYSICIANS ARE LIMITED

Outdated diagnostics leave specialists without precise data to guide care.

PATIENTS ARE LEFT IN THE DARK

Many couples endure years of uncertainty, costly treatments, and emotional strain—often without accurate answers.

↗ THE SOLUTION: PS DETECT

FIRST OF ITS KIND BIOMARKER TEST that identifies fertilization-capable sperm.

RESEARCH-BACKED AND CLINICALLY PROVEN to uncover causes of male infertility missed by traditional testing.

ACTIONABLE RESULTS that help physicians target effective treatments earlier—potentially avoiding unnecessary IVF cycles.

↗ KEY MESSAGES

BREAKTHROUGH DIAGNOSTIC INNOVATION: PS Detect identifies fertilization-capable sperm using the PS biomarker.

UNCOVERS WHAT OTHER TESTS MISS: Detects male infertility factors overlooked by standard semen analysis.

BACKED BY RESEARCH AND RESULTS: Developed by a team of fertility experts and supported by peer-reviewed data.

EMPOWERS BOTH PHYSICIANS AND PATIENTS: Turns confusion into clarity and uncertainty into action.

PATIENT STATISTICS

AT PS FERTILITY, WE LET THE DATA SPEAK FOR ITSELF.



INFERTILITY AFFECTS 1 IN 6 COUPLES WORLDWIDE

~50% of infertility cases are linked to male factors.

FROM EARLY COMMERCIAL USAGE OF PS SCORE BY OVER 30 PHYSICIANS, PRIMARILY REPRODUCTIVE UROLOGISTS, WE'VE DETERMINED:

- More than 1/3 of all male fertility patients tested fell below normal PS levels.
- 38% of patients had a PS Score below 78%.
- Scores ranged from 32% to 94%, and the average age of a patient tested was 35 years old.



20-30% OF MEN WITH A NORMAL STANDARD SEMEN ANALYSIS ARE INFERTILE

IN A 2024 STUDY PRESENTED AT THE AMERICAN UROLOGICAL ASSOCIATION, NEARLY HALF OF PATIENTS WHO HAD A VARICOCELE ALSO HAD A PS SCORE BELOW NORMAL.

- 44% of all varicocele patients had a PS Score below normal range, suggesting they were less fertile.
- 29% of patients had a normal semen analysis and a low PS Score—meaning they were misdiagnosed as fertile.
- 54% of patients had a normal semen analysis and a normal PS Score, meaning they were likely truly fertile.

QUOTES

“A ‘NORMAL’ SEMEN ANALYSIS RESULT IS NOT ALWAYS THE END OF THE STORY. MANY PATIENTS WHO EXPERIENCE UNEXPLAINED INFERTILITY HAVE BEEN TOLD THEIR SEMEN PARAMETERS ARE REASSURING, YET SOMETHING IS STILL PREVENTING CONCEPTION FROM HAPPENING. THAT’S WHERE DEEPER INSIGHTS ARE NEEDED MOST, HELPING TO PROVIDE ANSWERS WHERE PRESENTLY ONLY UNCERTAINTY LIES.”

Dr. Ryan Smith, Reproductive urologist at UVA Health and Chief Medical Officer at PS Fertility

“MALE INFERTILITY HAS LONG BEEN UNDERDIAGNOSED AND UNDERTREATED. BY FOCUSING ON ADVANCED DIAGNOSTICS LIKE PS DETECT, WE’RE PAVING THE WAY FOR MORE INFORMED TREATMENTS AND BETTER OUTCOMES FOR COUPLES FACING INFERTILITY.”

Dr. Ryan Smith, Reproductive urologist at UVA Health and Chief Medical Officer at PS Fertility

“PS FERTILITY IS EXCITED TO BRING MEANINGFUL NEW SCIENCE, DIAGNOSTICS AND TREATMENTS TO THE MALE POPULATION EXPERIENCING FERTILITY CHALLENGES.”

Kevin Combs, Co-founder and CEO

“WITH INFERTILITY IMPACTING 1 IN 6 COUPLES, THE NEED FOR IMPROVED FERTILITY DIAGNOSTICS HAS NEVER BEEN GREATER. PS FERTILITY IS PROUD TO LEAD THE WAY WITH TESTS THAT GO BEYOND TRADITIONAL SEMEN ANALYSIS.”

Jeff Lysiak, Co-founder and Chief Scientific Officer of PS Fertility

SAMPLE MEDIA COVERAGE

PS FERTILITY'S EXPERTISE AND LEADERSHIP HAVE BEEN FEATURED IN TOP PUBLICATIONS AND MEDIA OUTLETS.

↗ 29 NEWS

READ THE ARTICLE: [ALBEMARLE COUNTY COMPANY DEVELOPS AT-HOME MALE FERTILITY TESTS](#) *March 13, 2025*

↗ FEMTECH INSIDER

READ THE ARTICLE: [PS FERTILITY RAISES \\$3.5M SERIES A FOR MALE FERTILITY DIAGNOSTIC TEST](#) *June 24, 2025*

READ THE ARTICLE: [PS FERTILITY RECEIVES \\$1.7 MILLION NIH GRANT FOR MALE FERTILITY DIAGNOSTIC TEST](#) *September 26, 2025*

↗ PS FERTILITY HAS PRESENTED

OR BEEN FEATURED AT:

2025 ASRM MEETING

2025 SMRU FELLOWS SYMPOSIUM

2025 SSMR ANNUAL MEETING

2025 AUA ANNUAL MEETING

2025 AUA INNOVATION NEXUS

PRESS CONTACT

For media inquiries,
interviews, or
additional information,
please contact:

ERIN CAREW

Social Media Manager, TwoTone Creative
marketing@twotonecreative.com
515.864.6657

WWW.PSFERTILITY.COM

 PS Fertility Inc